Felty's syndrome

Patients with FS should be closely followed up by a rheumatologist and should have at least monthly blood tests to monitor FBC. Office of Rare Diseases Research: Felty's syndrome Opens in new window

If they are receiving disease-modifying anti-rheumatic drugs (DMARDs) or granulocyte colony-stimulating factor, they should be monitored regularly for development of adverse effects and to assess whether the dose should be modified.

Medical practitioners should be highly vigilant for the development of infections in patients with FS and should treat any infections promptly.